MRI demonstration of gadolinium deposition in bone after monthly triple-dose gadopentetate dimeglumine and correlation with frequency of hypophosphatemia

Bageac, Devin; DeBevits, John J.; Munbodh, Reshma; Kaplan, Joshua M.; Wu, Rong; DiCamillo, Paul A.; Hu, Chaoran; Wang, Yanlin; Karimeddini, David; Naismith, Robert T.; Dhib‐Jalbut, Suhayl; Wolansky, Leo

doi:10.1016/j.clinimag.2020.07.022

Cited by 8 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analysis of Gd bone deposition has been described in a separate report. 9 Patients from the original BECOME trial were consecutively enrolled at New Jersey Medical School from 16 February 2003 to 26 February 2005. Scans from 67 patients from the BECOME multiple sclerosis trial cohort (original cohort, n = 75) were available for analysis.…”

Section: Methodsmentioning

confidence: 99%

“… 7 Recent studies have demonstrated Gd deposition in bone using emission spectroscopy in ex vivo studies 8 and in live patients using MRI. 9 The question that remains unanswered from these preliminary studies is whether the deposition of Gd results in immediate or long-term cellular or physiologic effects of clinical significance in patients with normal renal function.…”

Section: Introductionmentioning

confidence: 99%

“…The purpose of that study was to compare the clinical efficacy of the immunomodulating therapeutic agents interferon beta-1b (Betaseron®; Bayer, Leverkusen, Germany) and glatiramer acetate (Copaxone®; Teva Neuroscience, Kansas City, MO, USA). A retrospective analysis of the data from that trial, which included serial bloodwork, showed that patients receiving serial triple-dose Gd-based contrast demonstrated a higher frequency of hypophosphatemia 9 and leukopenia when compared with pre-study levels. 11 This was true of both treatment arms.…”

Section: Introductionmentioning

confidence: 99%

“…A retrospective analysis of the data from that trial, which included serial bloodwork, showed that patients receiving serial triple-dose Gd-based contrast demonstrated a higher frequency of hypophosphatemia 9 and leukopenia when compared with pre-study levels. 11 This was true of both treatment arms. Furthermore, the frequency of hypophosphatemia was found to progressively increase with repeat triple doses over 12 months (only 4% of patients developed episodes of hypophosphatemia in the first 3 months of the study, but 26% developed hypophosphatemia over the last 3 months).…”

Section: Introductionmentioning

confidence: 99%

“…12 In addition, a retrospective analysis of the bone marrow signal intensity over 13 months of monthly triple-dose Gd contrast administration demonstrated a progressive increase in the mean T1 signal-to-noise ratio (S/N) in the medullary cavity (0.039/month, p < 0.0001), suggesting bone marrow Gd deposition. 9 The purpose of the present study was to investigate the potential associations among leukopenia, hypophosphatemia, and bone marrow T1 hyperintensity secondary to serial Gd administration.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Monthly triple-dose gadolinium administration: potential associations with leukopenia, hypophosphatemia, and bone marrow T1 hyperintensity

et al. 2022

Self Cite

View full text Add to dashboard Cite

Objective Monthly scanning with triple-dose gadopentetate dimeglumine has been shown to be associated with progressive increases in bone T1 hyperintensity, hypophosphatemia, and leukopenia. This study was performed to retrospectively investigate the potential associations among these phenomena. Methods This retrospective analysis involved patients who had received monthly triple-dose gadopentetate dimeglumine for up to 2 years as part of treatment for multiple sclerosis. Monthly magnetic resonance imaging scans of the brain (n = 67) were segmented to evaluate the signal intensity in the cranial marrow. Potential associations among the marrow T1 hyperintensity, serum phosphate concentration, and white blood cell count were examined. Results Patients in the no leukopenia group showed a statistically significant mean monthly increase in the bone marrow signal-to-noise ratio of 0.0430/month. Patients in the leukopenia group showed a mean monthly increase in the bone marrow signal-to-noise ratio of 0.0398/month, but this was not statistically significant. Patients in the hypophosphatemia group were significantly less likely to develop leukopenia than patients who had never developed hypophosphatemia. Conclusions Although monthly administration of triple-dose gadopentetate dimeglumine over 13 months has been associated with progressive increases in leukopenia, hypophosphatemia, and T1 signal intensity of bone, this study showed an inverse relationship between leukopenia and hypophosphatemia.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Monthly triple-dose gadolinium administration: potential associations with leukopenia, hypophosphatemia, and bone marrow T1 hyperintensity

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

Evaluation of gadolinium deposition in cortical bone using three‐dimensional ultrashort echo time quantitative susceptibility mapping: A preliminary study

Zhang,

Zhou,

Chen

et al. 2023

NMR in Biomedicine

View full text Add to dashboard Cite

The aim of the current study was to investigate the feasibility of three‐dimensional ultrashort echo time quantitative susceptibility mapping (3D UTE‐QSM) for the assessment of gadolinium (Gd) deposition in cortical bone. To this end, 40 tibial bovine cortical bone specimens were divided into five groups then soaked in phosphate‐buffered saline (PBS) solutions with five different Gd concentrations of 0, 0.4, 0.8, 1.2, and 1.6 mmol/L for 48 h. Additionally, eight rabbits were randomly allocated into three groups, consisting of a normal‐dose macrocyclic gadolinium‐based contrast agent (GBCA) group (n = 3), a high‐dose macrocyclic GBCA group (n = 3), and a control group (n = 2). All bovine and rabbit tibial bone samples underwent magnetic resonance imaging (MRI) on a 3‐T clinical MR system. A 3D UTE‐Cones sequence was utilized to acquire images with five different echo times (i.e., 0.032, 0.2, 0.4, 0.8, and 1.2 ms). The UTE images were subsequently processed with the morphology‐enabled dipole inversion algorithm to yield a susceptibility map. The average susceptibility was calculated in three regions of interest in the middle of each specimen, and the Pearson's correlation between the estimated susceptibility and Gd concentration was calculated. The bone samples soaked in PBS with higher Gd concentrations exhibited elevated susceptibility values. A mean susceptibility value of −2.47 ± 0.23 ppm was observed for bovine bone soaked in regular PBS, while the mean QSM value increased to −1.75 ± 0.24 ppm for bone soaked in PBS with the highest Gd concentration of 1.6 mmol/L. A strong positive correlation was observed between Gd concentrations and QSM values. The mean susceptibility values of rabbit tibial specimens in the control group, normal‐dose GBCA group, and high‐dose GBCA group were −4.11 ± 1.52, −3.85 ± 1.33, and −3.39 ± 1.35 ppm, respectively. In conclusion, a significant linear correlation between Gd in cortical bone and QSM values was observed. The preliminary results suggest that 3D UTE‐QSM may provide sensitive noninvasive assessment of Gd deposition in cortical bone.

show abstract

NMR thermosensor properties of lanthanide complexes with diethylenetriamine-N,N,N′,N″,N″-pentaacetic acid [Ln(H2O)(DTPA)]2− (Ln = Pr, Dy, Ho, Yb)

Zapolotsky

Babailov²

2022

Russ Chem Bull

View full text Add to dashboard Cite

MRI demonstration of gadolinium deposition in bone after monthly triple-dose gadopentetate dimeglumine and correlation with frequency of hypophosphatemia

Cited by 8 publications

References 29 publications

Monthly triple-dose gadolinium administration: potential associations with leukopenia, hypophosphatemia, and bone marrow T1 hyperintensity

Monthly triple-dose gadolinium administration: potential associations with leukopenia, hypophosphatemia, and bone marrow T1 hyperintensity

Evaluation of gadolinium deposition in cortical bone using three‐dimensional ultrashort echo time quantitative susceptibility mapping: A preliminary study

NMR thermosensor properties of lanthanide complexes with diethylenetriamine-N,N,N′,N″,N″-pentaacetic acid [Ln(H2O)(DTPA)]2− (Ln = Pr, Dy, Ho, Yb)

Contact Info

Product

Resources

About